- Business Wire•3 hours agoCombined Analysis of Oral Epigenetic Therapy, CC-486, Demonstrated Hematologic Responses in Patients Who Received Prior Epigenetic Hypo-Methylating Agents (HMA)
Abstract #905 -- Celgene Corporation , today announced results from an analysis of three phase I/II studies evaluating CC-486 in patients with myelodysplastic syndromes , chronic myelomonocytic leukemia and acute myeloid leukemia who had received prior hypomethylating agents were presented today at the 58th American Society of Hematology Annual Meeting in San Diego, Calif.
- Business Wire•5 hours agoAcceleron and Celgene Announce Updated Results from Phase 2 Studies of Luspatercept in Beta-Thalassemia Presented at the 58th Annual Meeting of the American Society of Hematology
Acceleron Pharma Inc. and Celgene Corporation today announced Phase 2 results from an open-label three-month base study and the ongoing long-term safety extension study with luspatercept in patients with beta-thalassemia during an oral presentation at the 58th Annual Meeting of the American Society of Hematology in San Diego, California.
- Investopedia•9 hours ago
Acceleron and Celgene are launching an ambitious trial to find a cure for a cancer-like blood disorder that will eliminate the need for blood transfusions.
CELG : Summary for Celgene Corporation - Yahoo Finance
Celgene Corporation (CELG)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||116.00 x 200|
|Ask||116.80 x 100|
|Day's Range||115.92 - 118.29|
|52 Week Range||93.05 - 127.00|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||44.27|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|